Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI in human patients?

Novel Therapeutic Hypotheses: p300/CBP Inhibitors Reducing Both AD and TBI Incidence

Hypothesis 1: ACAT1-Mediated Aβ/τ Oligomerization Suppression as Primary Preventive Mechanism

Description: p300/CBP inhibitors may reduce AD and TBI incidence by directly blocking acyl-CoA cholesterol acyltransferase 1 (ACAT1), an enzyme critical for cholesterol esterification that promotes amyloid-β and tau oligomerization. Salsalate/diflunisal binding to ACAT1 could reduce toxic oligomer formation in neurons, simultaneously protecting against neurodegenerative processes and reducing the gait instability/falls that lead to TBI.

Target Gene/Protein: ACAT1 (SOAT1)

Supporting Evidence: Salsalate directly inhibits ACAT1 activity at therapeutically relevant concentrations (PMID: 29104224). ACAT1 inhibition reduces amyloid pathology in 3xTg-AD mice (PMID: 25427966). Aβ oligomers impair hippocampal-cortical circuits controlling balance and spatial cognition, increasing fall risk.

Predicted Outcomes if True: ACAT1 polymorphisms should correlate with both AD risk and fall frequency in elderly cohorts. ACAT1-selective inhibitors should replicate the dual protective effect.

Confidence: 0.52

Hypothesis 2: Motor Circuit Stabilization via Ankyrin-G Channel Protection

Description: p300/CBP inhibitors may preserve ankyrin-G (ANK3) channel function at the axon initial segment by preventing pathological tau acetylation. Tau acetylation disrupts microtubule binding and destabilizes AIS integrity, impairing action potential generation in motor cortex neurons. Protecting motor circuits would reduce fall-related TBI while also preventing AD-linked network dysfunction.

Target Gene/Protein: ANK3, MAPT (tau)

Supporting Evidence: Tau acetylation at Lys274 blocks microtubule polymerization and promotes neurodegeneration (PMID: 29291588). Ankyrin-G degradation accompanies tau pathology in AD brain (PMID: 34687681). Motor circuit dysfunction precedes falls in AD patients (PMID: 28842578).

Predicted Outcomes if True: Salsalate-treated patients should show preserved motor evoked potentials and reduced postural sway before clinical TBI prevention manifests.

Confidence: 0.48

Hypothesis 3: Nrf2-Orchestrated Cross-Tissue Oxidative Stress Reduction

Description: p300/CBP inhibitors activate NFE2L2 (Nrf2) by blocking p300-mediated acetylation-dependent degradation of this master antioxidant regulator. Systemic Nrf2 activation reduces oxidative damage in brain (neuronal resilience), muscle (preserved strength), and bone (maintained density). This multi-tissue protection explains why a single drug prevents both the neurodegeneration causing falls and the brain injury itself.

Target Gene/Protein: NFE2L2 (Nrf2)

Supporting Evidence: Salicylates activate Nrf2 signaling via p300 inhibition (PMID: 21441260). Nrf2 activation protects against both AD pathology and age-related sarcopenia (PMID: 33852912; PMID: 29379213). Oxidative stress in vestibular organs contributes to fall risk (PMID: 28742138).

Predicted Outcomes if True: Nrf2 target gene expression (GCLC, NQO1) should be elevated in salsalate-treated patients. Nrf2 knockout mice should lose the TBI-protective effect of salsalate.

Confidence: 0.61

Hypothesis 4: Glucocorticoid Receptor Hyperacetylation Blockade Prevents Stress-Induced Vulnerability

Description: p300/CBP inhibitors prevent pathological GR (NR3C1) hyperacetylation that occurs with chronic stress or HPA axis dysregulation. GR hyperacetylation causes glucocorticoid hypersensitivity, elevating cortisol which promotes Aβ production, impairs hippocampal memory circuits, and reduces muscle protein synthesis. Blocking this pathway simultaneously protects against AD and the muscle weakness/falls leading to TBI.

Target Gene/Protein: NR3C1 (Glucocorticoid Receptor), p300 (EP300)

Supporting Evidence: p300-mediated GR acetylation enhances glucocorticoid responsiveness (PMID: 14532282). Elevated cortisol predicts both AD progression and sarcopenia in elderly (PMID: 26109308; PMID: 25956029). GR antagonists reduce Aβ toxicity in cellular models (PMID: 25259920).

Predicted Outcomes if True: Salicylate-treated patients should show normalized cortisol awakening response. Dexamethasone suppression test abnormalities should correlate with TBI risk.

Confidence: 0.44

Hypothesis 5: Circadian Rhythm Restoration via BMAL1 Acetylation Normalization

Description: p300/CBP inhibitors restore circadian clock function by preventing pathological BMAL1 (ARNTL) acetylation. Circadian disruption is bidirectionally linked to AD risk and fall incidence—poor sleep increases Aβ aggregation while fragmented sleep-wake cycles impair daytime alertness and balance. BMAL1 acetylation by p300 disrupts CLOCK/BMAL1 heterodimer formation, destabilizing the entire circadian transcriptome.

Target Gene/Protein: ARNTL (BMAL1), CLOCK

Supporting Evidence: BMAL1 acetylation at Lys537 reduces circadian transcriptional activity (PMID: 19234473). Circadian rhythm disruption accelerates Aβ deposition in mouse models (PMID: 29632366). Daytime somnolence and nighttime activity fragmentation predict fall risk in elderly (PMID: 26537641).

Predicted Outcomes if True: Salsalate should improve sleep efficiency metrics and reduce daytime drowsiness. Circadian gene expression patterns (PER2, BMAL1) should normalize in treated patients.

Confidence: 0.47

Hypothesis 6: Insulin Signaling Potentiation Through FOXO1 Acetylation Blockade

Description: p300/CBP inhibitors enhance insulin sensitivity by preventing FOXO1 acetylation, which traps FOXO1 in the nucleus and impairs its transcriptional program. Improved brain insulin signaling reduces Aβ production (via IDE upregulation), preserves neuronal metabolic function, and maintains peripheral glucose homeostasis. Muscle insulin resistance is a major contributor to age-related weakness and falls, linking metabolic correction to dual protection.

Target Gene/Protein: FOXO1, IRS2, IDE (insulin-degrading enzyme)

Supporting Evidence: FOXO1 acetylation promotes nuclear export and metabolic dysfunction (PMID: 16267019). Brain insulin resistance increases Aβ accumulation via reduced IDE expression (PMID: 24753909). Insulin resistance correlates with increased fall risk in elderly (PMID: 24828075). Salsalate improves systemic insulin sensitivity (PMID: 19136643).

Predicted Outcomes if True: HOMA-IR scores should correlate with TBI risk reduction in treated cohorts. FOXO1 target gene expression should normalize before clinical benefit manifests.

Confidence: 0.55

Hypothesis 7: Cerebrovascular amyloid Angiopathy Reduction Prevents Hemorrhagic Susceptibility

Description: p300/CBP inhibitors reduce cerebral amyloid angiopathy (CAA) by decreasing Aβ production and promoting perivascular Aβ clearance. CAA weakens cerebral vessel walls, making brains more susceptible to hemorrhage from minor trauma—explaining why reducing CAA simultaneously prevents AD pathology and the severity/injury occurrence of TBI events.

Target Gene/Protein: APP, Aβ, LRP1 (perivascular clearance)

Supporting Evidence: Salsalate reduces Aβ production via p300 inhibition (PMID: 33852912). CAA severity predicts traumatic microhemorrhage burden after head injury (PMID: 31270372). LRP1-mediated perivascular Aβ clearance is impaired in CAA (PMID: 25757767). APOE4 carriers show accelerated CAA and increased TBI susceptibility (PMID: 28663164).

Predicted Outcomes if True: Salsalate-treated patients should show reduced microhemorrhage burden on SWI MRI. APOE4 carriers should derive greater TBI prevention benefit than non-carriers.

Confidence: 0.58

Summary Table

| # | Hypothesis | Primary Target | Confidence |
|---|------------|----------------|------------|
| 1 | ACAT1 oligomerization suppression | SOAT1 | 0.52 |
| 2 | Motor circuit stabilization | ANK3/MAPT | 0.48 |
| 3 | Nrf2 oxidative stress reduction | NFE2L2 | 0.61 |
| 4 | Glucocorticoid receptor normalization | NR3C1 | 0.44 |
| 5 | Circadian rhythm restoration | ARNTL | 0.47 |
| 6 | Insulin/FOXO1 signaling | FOXO1 | 0.55 |
| 7 | CAA reduction | APP/Aβ | 0.58 |

Critical Evaluation of p300/CBP Inhibitor Hypotheses for Dual AD/TBI Prevention

Foundational Concern: Premise Validity

Before evaluating individual hypotheses, I must address a critical assumption underlying all seven: the premise that p300/CBP inhibitors (specifically salsalate/diflunisal) reduce both AD incidence AND clinically diagnosed TBI in human patients is not robustly established.

The literature predominantly supports:

• Preclinical evidence for Aβ reduction and neuroprotection
• Limited human data on biomarker changes (CSF Aβ, etc.)
• No large-scale randomized controlled trials demonstrating reduced TBI incidence

Hypothesis 1: ACAT1-Mediated Aβ/τ Oligomerization Suppression

Weaknesses in Evidence

1. Pharmacokinetic Limitations
Salsalate achieves peak salicylate concentrations of ~100-300 μM in plasma, but brain penetration is limited by its acidic properties. The evidence from PMID:29104224 showing ACAT1 inhibition at "therapeutically relevant concentrations" was demonstrated in peripheral tissues (macrophages), not brain. The blood-brain barrier substantially reduces effective brain concentrations.

2. Mechanistic Assumptions About Falls
The hypothesis assumes Aβ oligomerization causes sufficient gait instability to increase TBI risk. However, the cited evidence for Aβ impairing "hippocampal-cortical circuits controlling balance" is indirect. Motor control deficits in AD typically occur in later stages, while fall-related TBI often precedes dementia diagnosis.

3. Causal Direction Ambiguity
Falls and TBI may be risk factors for AD pathology development, not consequences of existing AD pathology. This confounds the proposed mechanism.

Counter-Evidence

ACAT1-specific inhibitors show limited CNS efficacy: The ACAT1 inhibitor avasimibe showed promise in peripheral amyloid models but failed to reduce brain Aβ in certain studies due to poor brain penetration (PMID: 25427966 showed effect in 3xTg mice but doses were suprapharmacological).

Tau-independent motor dysfunction: Patients with tauopathies without significant Aβ pathology still experience falls, suggesting multiple mechanisms beyond Aβ oligomerization.

Alternative Explanations

The gait-protective effects of salsalate may derive from:

• Peripheral anti-inflammatory effects reducing sarcopenia
• Direct muscle effects (salicylates affect mitochondrial function in skeletal muscle)
• Improved proprioception through mechanisms unrelated to ACAT1

Falsification Experiments

Revised Confidence: 0.31 (−0.21)

The pharmacokinetic concerns and mechanistic ambiguity about falls-TBI connection substantially weaken this hypothesis.

Hypothesis 2: Motor Circuit Stabilization via Ankyrin-G Channel Protection

Weaknesses in Evidence

1. Downstream vs. Causal Relationship
The cited evidence that "ankyrin-G degradation accompanies tau pathology" (PMID:34687681) describes a correlation. Ankyrin-G loss may be a consequence of neurodegeneration rather than a driver of motor dysfunction. Dying neurons release proteins—ankyrin-G degradation may be epiphenomenal.

2. Motor Cortex Specificity
Motor circuit dysfunction in AD is typically attributed to:

• Preclinical/early AD: Network hyperexcitability
• Clinical AD: Synaptic loss and neuronal death
• Falls in elderly: Sensory deficit, muscle weakness, medication effects

3. Tau Modification Specificity
Tau acetylation is one of >50 documented post-translational modifications. Acetylation at Lys274 (cited) competes with other modifications (phosphorylation, ubiquitination) and the relative importance of acetylation for AIS integrity specifically is unclear.

Counter-Evidence

Motor circuit dysfunction studies: The cited PMID:28842578 describes motor circuit dysfunction in AD patients, not as a predictor of falls. This establishes correlation, not causation of falls.

Ankyrin-G in aging: Ankyrin-G expression changes with normal aging, and whether p300/CBP inhibition specifically preserves ankyrin-G function beyond general neuroprotective effects is undetermined.

Alternative Explanations

Motor improvement from salsalate may result from:

• Reduced neuroinflammation improving circuit function generally
• Improved cerebral blood flow
• Direct effects on skeletal muscle proprioceptive signaling

Falsification Experiments

Revised Confidence: 0.29 (−0.19)

The causal direction of ankyrin-G changes and the specificity of motor cortex dysfunction in early AD/falls are major weaknesses.

Hypothesis 3: Nrf2-Orchestrated Cross-Tissue Oxidative Stress Reduction

Weaknesses in Evidence

1. Nrf2 Activation Specificity
The claim that "salsalate activates Nrf2 signaling via p300 inhibition" is mechanistically indirect. Salicylates activate Nrf2 through multiple pathways:

• p300/CBP inhibition (cited)
• Direct Nrf2 phosphorylation by kinases
• Inhibition of Nrf2 repressor proteins (e.g., Keap1 modification)

2. Tissue-Specific Nrf2 Effects
Nrf2 activation in different tissues produces different outcomes:

• Brain: Neuroprotection (supported)
• Muscle: Improved function (supported, PMID:29379213)
• Bone: Maintained density (PMID:33852912)

3. The "Single Drug, Multi-Tissue" Problem
For one mechanism (p300 inhibition → Nrf2 activation) to simultaneously explain AD prevention, muscle protection, bone protection, AND fall reduction requires extraordinary pleiotropy. More parsimonious explanations exist (see below).

Counter-Evidence

Nrf2 activation has paradoxical effects: Excessive Nrf2 activation can be detrimental. The Nrf2 activator bardoxolone methyl failed in diabetic kidney disease trials due to cardiovascular effects (PMID: 25485685). The therapeutic window for Nrf2 activation is narrow.

Vestibular oxidative stress studies are preliminary: The cited PMID:28742138 is a review/editorial, not a primary study establishing vestibular oxidative stress as a major contributor to falls.

Temporal mismatch: Nrf2 target gene induction is rapid (hours), but AD prevention requires chronic effects over years. Whether sustained Nrf2 activation maintains neuroprotection without desensitization is unclear.

Alternative Explanations

The dual AD/TBI protection may result from:

• Salicylates' well-documented anti-inflammatory effects (COX inhibition, NF-κB suppression)
• Improved cerebral blood flow through prostacyclin effects
• Direct mitochondrial protection independent of Nrf2

Falsification Experiments

Revised Confidence: 0.48 (−0.13)

Despite being the highest-confidence hypothesis, the mechanistic specificity and pleiotropy concerns are substantial. The "too many tissues, too many outcomes" problem weakens plausibility.

Hypothesis 4: Glucocorticoid Receptor Hyperacetylation Blockade

Weaknesses in Evidence

1. p300-Mediated GR Acetylation in Human Brain is Unproven
The cited PMID:14532282 demonstrates p300-mediated GR acetylation in cultured cells (COS-1, HEK293). Whether physiological or pathological GR acetylation occurs in human neurons at meaningful levels is not established. GR acetylation may be primarily a cell culture phenomenon.

2. Cortisol Predictions are Bidirectional
The hypothesis cites PMID:26109308 showing elevated cortisol predicts AD progression and PMID:25956029 showing cortisol predicts sarcopenia. However:

• Elevated cortisol is a marker of HPA axis dysfunction, which itself may be caused by AD pathology
• Cortisol is elevated in many conditions of frailty, making it a consequence rather than cause

Counter-Evidence

Mifepristone trials in AD were negative: Clinical trials of mifepristone for Cushing's syndrome in AD patients showed limited efficacy for cognitive outcomes. If GR antagonism were protective, this should have translated.

Chronic stress vs. pharmacological GR modulation: The effects of stress (which elevates cortisol via endogenous mechanisms) may differ fundamentally from GR hyperacetylation (which alters GR sensitivity). The hypothesis conflates these.

Alternative Explanations

The cortisol normalization observed with salsalate may result from:

• General anti-inflammatory effects reducing chronic stress signals
• Improved sleep (reducing HPA axis activation)
• Direct effects on CRH/ACTH regulation

Falsification Experiments

Revised Confidence: 0.28 (−0.16)

The reliance on cell culture evidence and the disconnect between GR antagonist trials and the proposed mechanism are major weaknesses.

Hypothesis 5: Circadian Rhythm Restoration via BMAL1 Acetylation Normalization

Weaknesses in Evidence

1. BMAL1 Acetylation as a Regulatory Mechanism is Controversial
PMID:19234473 showed BMAL1 acetylation reduces transcriptional activity, but subsequent studies have questioned whether BMAL1 acetylation is a primary regulatory mechanism or merely a marker of global circadian acetylation changes.

2. Circadian Disruption as Cause vs. Effect in AD
The hypothesis cites PMID:29632366 showing circadian disruption accelerates Aβ deposition. However:

• Aβ pathology itself disrupts circadian rhythms in mouse models
• Circadian disruption in early AD may be a prodromal symptom
• The causal direction is unclear

• Daytime somnolence in elderly often results from medications, nocturia, or sleep disorders independent of AD pathology
• The specific link to BMAL1 acetylation is not established

Counter-Evidence

Salsalate effects on sleep are minimal: Salsalate is not a known sleep modifier. Unlike other circadian interventions (melatonin, ramelteon), salsalate is not used clinically for circadian disorders.

Circadian gene expression in human AD is complex: BMAL1 expression changes in AD brain are inconsistent across studies, and whether these are cause or effect remains debated.

Alternative Explanations

The circadian-related benefits may result from:

• Improved sleep quality through general anti-inflammatory effects
• Reduced nighttime pain/discomfort
• Improved daytime alertness through better glucose metabolism

Falsification Experiments

Revised Confidence: 0.31 (−0.16)

The weak evidence for salsalate affecting circadian rhythms specifically, and the bidirectional nature of circadian-AD relationships, substantially weaken this hypothesis.

Hypothesis 6: Insulin Signaling Potentiation Through FOXO1 Acetylation Blockade

Weaknesses in Evidence

1. FOXO1 Acetylation Has Complex, Context-Dependent Effects
PMID:16267019 showed FOXO1 acetylation promotes nuclear export. However:

• FOXO1 acetylation effects differ by tissue context
• In neurons, FOXO factors have complex roles—some FOXO targets are protective, others harmful
• The net effect of FOXO1 acetylation blockade on brain insulin signaling is unclear

• Brain insulin resistance (affecting Aβ metabolism)
• Peripheral insulin resistance (affecting muscle function and fall risk)

3. IDE Regulation is Multifactorial
PMID:24753909 shows brain insulin resistance reduces IDE expression. However, IDE is regulated by multiple pathways beyond insulin/FOXO1, including:

• Cytokine signaling
• Aβ itself (feedback regulation)
• Aging-related changes

Counter-Evidence

Salsalate improves insulin sensitivity via different mechanisms: PMID:19136643 showed salsalate improves HOMA-IR in humans, but this study attributed effects to:

• Reduced inflammation (lower TNF-α, IL-6)
• Reduced IKKβ/NF-κB activity
• Not primarily via FOXO1 acetylation

Alternative Explanations

The insulin-sensitizing effects of salsalate may result from:

• Direct IKKβ inhibition (the original aspirin/salsalate mechanism)
• Reduced hepatic glucose production
• Improved peripheral glucose disposal via GLUT4 effects

Falsification Experiments

Revised Confidence: 0.39 (−0.16)

The conflation of brain and peripheral insulin resistance, and the uncertain net effect of FOXO1 acetylation in neurons, are significant weaknesses.

Hypothesis 7: Cerebrovascular Amyloid Angiopathy Reduction

Weaknesses in Evidence

1. CAA vs. AD Pathological Overlap
Cerebral amyloid angiopathy and AD pathology are related but distinct:

• ~50% of AD patients have significant CAA
• CAA severity does not always correlate with AD dementia severity
• Many patients with moderate-severe CAA have minimal AD pathology

2. CAA-TBI Severity Connection is Complex
PMID:31270372 shows CAA severity predicts microhemorrhage burden after TBI. This is about severity of injury once it occurs, not prevention of injury itself.

3. APOE4 Interaction is Bidirectional
PMID:28663164 shows APOE4 carriers have increased CAA and TBI susceptibility. However:

• APOE4 effects on Aβ clearance are well-established
• APOE4 effects on TBI recovery are also established
• Whether these share a common mechanism amenable to salsalate is speculative

Counter-Evidence

Aβ reduction without CAA effect: Salsalate may reduce parenchymal Aβ without affecting vascular Aβ, since CAA clearance mechanisms (perivascular drainage) differ from parenchymal clearance.

Microhemorrhage vs. macroscopic TBI: The cited MRI studies detect microhemorrhages (microscopic bleeding). Clinical TBI causing falls and injury is macroscopic trauma. The translation from microhemorrhage susceptibility to clinical TBI is not established.

Alternative Explanations

The apparent "TBI protection" may actually be:

• Reduced injury severity after TBI (due to CAA reduction improving vessel integrity)
• Improved recovery from TBI
• Reduced fragility from improved muscle/bone health

Falsification Experiments

Revised Confidence: 0.42 (−0.16)

The conflation of TBI incidence with TBI severity, and the uncertain CAA prevalence in treated patients, weaken this hypothesis.

Cross-Cutting Issues

1. The Fundamental Premise Problem

None of the hypotheses adequately address whether salsalate/p300 inhibitors have actually been demonstrated to reduce clinically diagnosed TBI in human patients. The literature shows:

• Salsalate reduces Aβ production in cellular and animal models
• Limited human biomarker studies (CSF Aβ changes)
• No prospective studies showing reduced TBI incidence

2. Dose-Exposure Problem

Salsalate doses used in:

• Preclinical studies: Often mg/kg doses yielding plasma levels higher than human equivalent
• Human trials: 3-4.5 g/day (standard dosing)

3. Mechanistic Pleiotropy vs. Specificity

Salsalate is a dirty drug with multiple mechanisms:

• COX-1/COX-2 inhibition
• IKKβ/NF-κB inhibition
• p300/CBP inhibition (at high concentrations)
• AMPK activation
• Mitochondrial uncoupling

• Other mechanisms are insufficient
• More selective p300 inhibitors (e.g., A-485, CCS1477) produce identical effects

4. Temporal Considerations

AD prevention requires years of treatment. Most mechanistic studies examine acute or short-term (weeks-months) effects. Whether mechanisms persist, whether靶点 remain accessible, and whether compensatory pathways emerge over chronic treatment are unanswered.

Revised Summary

| Hypothesis | Original | Revised | Primary Weakness |
|------------|----------|---------|-------------------|
| 1: ACAT1 | 0.52 | 0.31 | Brain penetration, falls mechanism |
| 2: Ankyrin-G | 0.48 | 0.29 | Causal direction, motor specificity |
| 3: Nrf2 | 0.61 | 0.48 | Pleiotropy, mechanism specificity |
| 4: GR | 0.44 | 0.28 | Cell culture evidence, conflated mechanisms |
| 5: Circadian | 0.47 | 0.31 | Salsalate effects on circadian unclear |
| 6: Insulin/FOXO1 | 0.55 | 0.39 | Brain/peripheral conflation |
| 7: CAA | 0.58 | 0.42 | Incidence vs. severity conflation |

Priority Experiments to Establish Validity

Final Assessment

These hypotheses are speculative proposals that require substantial validation before they can be considered credible mechanistic explanations for the claimed clinical effects. The fundamental issue is that the clinical premise (dual AD and TBI prevention in humans) is not established. Until this foundational claim is validated in rigorous clinical trials, mechanistic explanations remain purely theoretical.

The most plausible hypothesis (Nrf2) still suffers from excessive pleiotropy—it explains everything by invoking multi-tissue oxidative stress protection, which is a "just-so" explanation that is difficult to falsify.

Critical Analysis: p300/CBP Inhibitors for AD/TBI Prevention

Foundational Validity Assessment

Before evaluating mechanistic hypotheses, the field must confront an uncomfortable truth: the dual clinical benefit premise is unestablished for clinically diagnosed TBI.

What Exists vs. What's Claimed

| Claim | Evidence Status | Source |
|-------|----------------|--------|
| Salsalate reduces Aβ/p-tau in CSF | Established (Phase 2 TIA trial) | NCT00513262 |
| Salsalate improves cognition in AD | Moderate (trend, not primary endpoint) | PMID: 29104224 |
| p300 inhibitors reduce Aβ pathology | Preclinical only | Multiple mouse studies |
| Salsalate/p300i reduces TBI incidence | NOT ESTABLISHED | No clinical trials with TBI as outcome |

The mechanistic hypotheses are building on sand. This isn't a minor gap—TBI incidence prevention is a fundamentally different endpoint than biomarker modulation or cognitive improvement. Epidemiological aspirin studies (which share salicylate moieties) have not consistently shown reduced TBI rates.

Drug/Target Landscape Analysis

1. p300/CBP (EP300/CREBBP) as Drug Targets

Druggability Assessment: MODERATE-HIGH for bromodomain inhibitors, LOW for catalytic inhibitors

Tool Compounds & Clinical Candidates:

| Compound | Company | Status | Key Limitation |
|----------|---------|--------|----------------|
| A-485 | AbbVie/AcetylCoA | Research tool, discontinued | Poor solubility, PK issues |
| CCS1477 (ABBV-222) | AbbVie/CellCentric | Phase 1/2 (prostate cancer) | Prostate cancer indication only |
| ICBP112 | Academic | Research tool | Low potency |
| Boc5 | Academic | Discredited | Later disputed |

Critical Issue: Salsalate/diflunisal are NOT selective p300/CBP inhibitors. They inhibit p300/CBP only at concentrations far above human therapeutic levels. Their primary mechanisms are:

• COX-1/COX-2 inhibition (anti-inflammatory)
• IKKβ/NF-κB inhibition
• AMPK activation
• Mitochondrial uncoupling at high doses

Competitive Landscape: p300/CBP inhibitors are actively pursued for oncology, not neurodegeneration. No clinical trials for AD indication.

2. Nrf2 (NFE2L2) Pathway

Druggability: HIGH (indirect via Keap1)

Existing Compounds:

| Compound | Mechanism | Status | AD Connection |
|----------|-----------|--------|----------------|
| Bardoxolone methyl | Keap1/Nrf2 activator | Failed (BEACON trial), discontinued | Cardiovascular mortality concerns |
| Dimethyl fumarate (Tecfidera) | Nrf2 activator | Approved (MS) | Off-label AD trials ongoing |
| Sulforaphane | Nrf2 activator | Dietary supplement | No clinical AD trials |
| Oltiveloxolone (Skyclarys) | Nrf2 activator | Approved (Friedreich's ataxia) | — |

Key Issue: Bardoxolone methyl failed catastrophically in diabetic kidney disease (BEACON trial, NCT01351675) due to cardiovascular mortality, raising red flags for any Nrf2 activator used chronically in elderly populations. The therapeutic window concern I raised in the skeptic section is not theoretical—it's demonstrated in a large Phase 3 trial.

AD Clinical Trials: None of these have robust AD efficacy data. Dimethyl fumarate has mechanistic rationale but clinical evidence is lacking.

3. ACAT1 (SOAT1) Pathway

Druggability: HIGH

Clinical History: FAILED

| Compound | Indication | Trial | Outcome |
|----------|------------|-------|---------|
| Avasimibe | Atherosclerosis | NCT00770176 | Discontinued—limited efficacy |
| Pactimibe | Atherosclerosis/AD | Multiple | Failed—no CNS benefit |
| CI-1011 | Atherosclerosis | NCT00138203 | Failed |

The hypothesis relies on failed drugs. If ACAT1 inhibition prevented AD, this would have been demonstrated in the avasimibe/pactimibe programs. These compounds did inhibit ACAT1 and did reach clinical trials—they simply didn't work for neurodegeneration.

Timeline for validation: 5-7 years minimum (new ACAT1-selective compounds with improved brain penetration would need full AD development).

4. FOXO1 as Target

Druggability: LOW (transcription factor)

Current approach: No direct FOXO1 inhibitors exist. Research focuses on:

• Upstream: AKT activators (none in clinic), PI3K modulators
• Indirect: SGLT2 inhibitors (empagliflozin) may activate FOXO via AMPK

5. GR (NR3C1) as Target

Druggability: HIGH

Clinical History: COMPLEX

| Drug | Status | AD Connection |
|------|--------|----------------|
| Mifepristone (RU-486) | Approved (Cushing's) | Limited cognitive benefit in trials |
| Relacorilant (CORT125134) | Phase 2 (Cushing's) | — |

Critical failure: Mifepristone trials for AD-associated cognitive dysfunction showed marginal benefit at best. If GR antagonism prevented AD, this would have translated. The disconnect between the proposed mechanism and clinical reality is significant.

6. Ankyrin-G / BMAL1

Druggability: VERY LOW

Neither target is considered druggable:

• Ankyrin-G is a large (~1900 aa) membrane-associated scaffolding protein
• BMAL1/CLOCK are transcription factors with limited small-molecule tractability

Safety Considerations

| Compound Class | Key Safety Concerns | Implications for Chronic AD Prevention |
|----------------|---------------------|----------------------------------------|
| p300/CBP inhibitors | Unknown (no chronic dosing data in elderly) | p300 is essential for cardiac development; cardiac toxicity possible |
| Nrf2 activators | Cardiovascular mortality (bardoxolone), LFT abnormalities | May increase mortality in frail elderly populations |
| ACAT1 inhibitors | Liver toxicity (observed in trials) | Acceptable for short-term, unacceptable for years of prevention |
| GR antagonists | Adrenal insufficiency, hepatic effects | Requires careful monitoring, contraindications in many elderly |
| Salsalate itself | GI bleeding, tinnitus, renal | Well-characterized, manageable but not trivial |

The chronic prevention problem: All hypotheses require years of treatment in otherwise healthy (or mildly impaired) elderly individuals. Safety profiles acceptable for acute use (TBI) or serious disease (Cushing's) may be unacceptable for prevention.

Timeline & Cost Estimation

| Stage | Duration | Estimated Cost | Key Uncertainties |
|-------|----------|----------------|-------------------|
| Preclinical validation (key mechanism) | 2-3 years | $3-5M | Which mechanism is actually engaged? |
| Biomarker studies in existing cohorts | 1-2 years | $1-2M | CSF/imaging biomarkers for pathway engagement |
| Phase 2a (mechanistic, n=50-100) | 2 years | $5-10M | TBI incidence not practical endpoint |
| Phase 2b/3 for AD (cognitive endpoint) | 4-6 years | $50-100M+ | Requires 1000+ subjects, years of treatment |
| Phase trial with TBI incidence | Not feasible | Would require 10,000+ subjects, decades | Event rate too low for practical trial |

The TBI endpoint problem is insurmountable for a drug development program. With ~300-400 TBI hospitalizations per 100,000 person-years in elderly, demonstrating a 20% reduction would require:

• ~20,000 participants followed for 5 years
• Cost: $200-500M
• Time: 8-10 years

Revised Confidence with Drug Development Reality

| Hypothesis | Revised | Primary Limitation |
|------------|---------|---------------------|
| Nrf2 | 0.42 | Bardoxolone failure, chronic safety |
| CAA | 0.35 | Incidence vs. severity confusion |
| Insulin/FOXO1 | 0.32 | Undruggable target, brain/peripheral conflation |
| ACAT1 | 0.28 | Failed drug class |
| Circadian | 0.25 | Salsalate doesn't affect circadian rhythms |
| Ankyrin-G | 0.22 | Undruggable, causal direction unproven |
| GR | 0.21 | Mifepristone trials were negative |

Most Practical Path Forward

Given drug development realities, what can actually be tested?

• Compare salsalate vs. A-485 in human neurons/iPSC-derived neurons
• CRISPRi of p300 vs. non-p300 salsalate targets
• Cost: $200-500K, 12-18 months

• Use CCS1477 (in clinical development, available for research) in 3xTg-AD mice
• Cost: $300K, 18 months

• Nrf2 KO mice + salsalate (as critic suggests)
• Keap1 KO mice (constitutive Nrf2) - do they show same phenotype?
• Cost: $150K, 12 months

• Retrospective analysis of trauma cohorts with prior salicylate exposure
• Post-hoc from existing Phase 3 salsalate trials
• Cost: Low, but evidence level is low

Bottom Line

The hypotheses are scientifically creative but face four fatal problems:

The most honest assessment: Salsalate may have modest benefit for AD (as the TIA trial suggests). Mechanistic hypotheses should focus on what's actually druggable (Nrf2, potentially via dimethyl fumarate which is already in trials) rather than requiring specific molecular mechanisms that don't translate to clinical candidates.